Key result
Alterations of hemostasis during cardiopulmonary bypass are primarily driven by functional platelet defects and hyperfibrino(geno)lysis, manageable with preoperative screening and targeted therapy.
Population
Patients undergoing cardiopulmonary bypass (CPB)
Design
Review
Authors
Loading...
May inform targeted hemostasis strategies in CPB; leaves open need for prospective randomized validation.
Altered hemostasis during CPB is primarily due to functional platelet defects and hyperfibrinolysis, which can be managed with adequate preoperative screening and targeted therapy like platelet concentrates or antifibrinolytics.
Rodger L. Bick (2008) conducted a review in Hemostasis alterations associated with cardiopulmonary bypass. Cardiopulmonary bypass was evaluated. Alterations of hemostasis during cardiopulmonary bypass are primarily driven by functional platelet defects and hyperfibrino(geno)lysis, manageable with preoperative screening and targeted therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: